Biodesix, Inc.
Louisville, CO
- UEI
- RPULDMFCXWF4
- CAGE
- 6T0H7
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 919 W Dillon Rd, Louisville, CO 80027, USA
- Website
- biodesix.com
- Founded
- 2005
- Employees
- 51-250
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | -$374,914 |
| FY2026 | -$237,477 |
| FY2025 | $690,901 |
| FY2024 | -$39,542 |
| FY2023 | $123,950 |
Contract vehicles
No active vehicles.
1 expired vehicle
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Neogenomics Laboratories, Inc. | Fort Myers, FL | 541380 Testing Laboratories and Services |
| Foundation Medicine, Inc. | Boston, MA | 621511 Medical Laboratories |
| Naveris Inc. | Waltham, MA | 621511 Medical Laboratories |
| Veracyte, Inc. | South San Francisco, CA | 621511 Medical Laboratories |
| Biocartis US Inc. | Itasca, IL | 334516 Analytical Laboratory Instrument Manufacturing |
About the company
Biodesix, Inc., headquartered in Boulder, Colorado, provides blood-based lung cancer screening and diagnostic testing services exclusively to the Department of Veterans Affairs as a prime contractor, competing in full-and-open procurements with no set-aside designations. The company is a for-profit medical laboratory specializing in proprietary lung disease diagnostics (Nodify and STX Nodify platforms) delivered through firm fixed-price delivery orders and blanket purchase agreements across multiple VA regional networks (Veterans Integrated Service Networks).
Customer concentration is absolute within the federal footprint: all 25 awards in the source data come from VA regional networks, with the top five VISNs accounting for 96% of recent awards. By dollar value, the portfolio is anchored by a single $20.3 million multiple-award Federal Supply Schedule contract (FSS-621-II, Medical Laboratory Testing and Analysis Services) awarded to VISN 12 in October 2022 with an ultimate completion date of October 2027. That vehicle alone represents 82% of combined potential value across all awards. VISN 17 follows distantly with five awards totaling $3 million in combined potential value, while VISN 23, VISN 8, and VISN 1 round out the active set with smaller delivery orders and blanket purchase agreements. The gap between award count and dollar concentration signals that most orders (delivery orders against the FSS schedule and single-award IDIQs and BPAs) carry sub-$500 thousand individual ceilings, with the exception of recent BPA calls to VISN 17 ($250 thousand and $2.25 million ceilings established July 2026 and October 2024, respectively).
Biodesix holds five parent vehicle positions: the $20.3 million GSA Federal Supply Schedule contract (9 task orders, $3.6 million combined potential value), two single-award indefinite delivery contracts with VISN 23 ($700 thousand ceiling, 6 task orders) and VISN 8 ($216.7 thousand ceiling, 3 task orders), and two single-award blanket purchase agreements with VISN 17 ($2.25 million and $250 thousand ceilings, respectively). Performance occurs at Biodesix's facility in Boulder, Colorado, with work supporting VA medical centers across the Minneapolis, Fargo, and Caribbean Healthcare System regions.
Activity has declined over the past five years: six awards in 2022, four in 2023 and 2024, and two each in 2025 and 2026. Within the next twenty-four months, three awards (combined potential value $442 thousand) reach ultimate completion date and face recompete exposure. The most recent award (July 1, 2026) is a $40.7 thousand BPA call to VISN 17 for VCB lung cancer screening services, completing June 30, 2027. Biodesix operates as a 100% prime footprint with no subcontract activity in the source data. The company's market position is highly specialized and dependent on continued VA adoption of blood-based lung cancer screening across regional networks; the portfolio lacks geographic or customer diversification outside VA healthcare.
Quick answers
Is Biodesix, Inc. registered in SAM.gov?
Yes. Biodesix, Inc.'s SAM.gov registration is active through December 18, 2026.
What is Biodesix, Inc.'s CAGE code?
Biodesix, Inc.'s CAGE code is 6T0H7, and its Unique Entity ID (UEI) is RPULDMFCXWF4.
Which contract vehicles does Biodesix, Inc. hold?
Biodesix, Inc. holds a place on 1 federal contract vehicle: FSS-621-II.
How much has Biodesix, Inc. received in federal contracts?
Federal contracts obligated $690,901 to Biodesix, Inc. in fiscal year 2025 and $162,918 in fiscal years 2023 through 2027.
How does Biodesix, Inc. rank among federal contractors?
Biodesix, Inc. ranked #54 in NAICS 621511, #73 in NAICS 6215 and #75 in PSC Q3 in FY2025.
What is Biodesix, Inc.'s most recent federal award?
Biodesix, Inc.'s most recent federal contract award is VCB lung cancer screening services (36C25726N0382), from Veterans Integrated Service Network 17 (VHA), on July 1, 2026.
On GovTribe
See Biodesix, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors